Bark said it received a non-binding proposal to be taken private. The stock jumped 29% to 80 cents in after-hours trading Friday.
Zentalis Pharmaceuticals said it completed enrollment for a Phase 2 trial and expects to start a confirmatory Phase 3 trial for a different drug in the first half of this year. Shares rose 22% to $4.56 after the bell.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 09, 2026 18:53 ET (23:53 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.